SNY vs. NVO, AZN, NVS, GSK, TAK, ARGX, BNTX, ONC, TEVA, and SMMT
Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Novo Nordisk A/S (NVO), AstraZeneca (AZN), Novartis (NVS), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.
Sanofi vs.
Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.
Novo Nordisk A/S has a net margin of 34.81% compared to Sanofi's net margin of 12.77%. Novo Nordisk A/S's return on equity of 84.68% beat Sanofi's return on equity.
In the previous week, Novo Nordisk A/S had 58 more articles in the media than Sanofi. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 20 mentions for Sanofi. Sanofi's average media sentiment score of 1.02 beat Novo Nordisk A/S's score of 0.54 indicating that Sanofi is being referred to more favorably in the news media.
Novo Nordisk A/S has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
Novo Nordisk A/S has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.
Novo Nordisk A/S received 377 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 61.79% of users gave Novo Nordisk A/S an outperform vote while only 60.98% of users gave Sanofi an outperform vote.
Novo Nordisk A/S pays an annual dividend of $1.57 per share and has a dividend yield of 1.8%. Sanofi pays an annual dividend of $1.47 per share and has a dividend yield of 2.7%. Novo Nordisk A/S pays out 47.7% of its earnings in the form of a dividend. Sanofi pays out 59.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Novo Nordisk A/S currently has a consensus price target of $145.25, indicating a potential upside of 64.93%. Sanofi has a consensus price target of $60.00, indicating a potential upside of 10.17%. Given Novo Nordisk A/S's higher possible upside, research analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.
Summary
Novo Nordisk A/S beats Sanofi on 13 of the 21 factors compared between the two stocks.
Get Sanofi News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:SNY) was last updated on 2/21/2025 by MarketBeat.com Staff
